WO2011071280A2 - 세포내 타겟 결합용 바이포달 펩타이드 바인더 - Google Patents
세포내 타겟 결합용 바이포달 펩타이드 바인더 Download PDFInfo
- Publication number
- WO2011071280A2 WO2011071280A2 PCT/KR2010/008646 KR2010008646W WO2011071280A2 WO 2011071280 A2 WO2011071280 A2 WO 2011071280A2 KR 2010008646 W KR2010008646 W KR 2010008646W WO 2011071280 A2 WO2011071280 A2 WO 2011071280A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- type
- peptide
- bipodal
- trp
- thr
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 330
- 239000011230 binding agent Substances 0.000 title claims abstract description 190
- 230000008685 targeting Effects 0.000 title claims abstract description 26
- 230000027455 binding Effects 0.000 claims abstract description 80
- 230000003834 intracellular effect Effects 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 55
- 150000001413 amino acids Chemical class 0.000 claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 claims description 134
- 210000004027 cell Anatomy 0.000 claims description 123
- 102000004169 proteins and genes Human genes 0.000 claims description 97
- 230000006641 stabilisation Effects 0.000 claims description 64
- 238000011105 stabilization Methods 0.000 claims description 64
- 239000013598 vector Substances 0.000 claims description 44
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 33
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 33
- -1 Transport an Proteins 0.000 claims description 24
- 230000003993 interaction Effects 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- BECPPKYKPSRKCP-ZDLURKLDSA-N Thr-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BECPPKYKPSRKCP-ZDLURKLDSA-N 0.000 claims description 14
- 230000001086 cytosolic effect Effects 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 12
- IEFJWDNGDZAYNZ-BYPYZUCNSA-N Gly-Glu Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(O)=O IEFJWDNGDZAYNZ-BYPYZUCNSA-N 0.000 claims description 11
- 108010002311 N-glycylglutamic acid Proteins 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 10
- OWOFCNWTMWOOJJ-WDSKDSINSA-N Gln-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O OWOFCNWTMWOOJJ-WDSKDSINSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims description 7
- 108010054155 lysyllysine Proteins 0.000 claims description 7
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 6
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 108090000353 Histone deacetylase Proteins 0.000 claims description 5
- 102000003964 Histone deacetylase Human genes 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000002689 Toll-like receptor Human genes 0.000 claims description 4
- 108020000411 Toll-like receptor Proteins 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 230000009881 electrostatic interaction Effects 0.000 claims description 4
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 4
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 241001515965 unidentified phage Species 0.000 claims description 4
- 101100248440 Danio rerio ric8b gene Proteins 0.000 claims description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 3
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 claims description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 claims description 3
- 102100026808 Mitochondrial import inner membrane translocase subunit Tim8 A Human genes 0.000 claims description 3
- 108010088535 Pep-1 peptide Proteins 0.000 claims description 3
- 101710149951 Protein Tat Proteins 0.000 claims description 3
- 101710192266 Tegument protein VP22 Proteins 0.000 claims description 3
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 claims description 3
- 230000023555 blood coagulation Effects 0.000 claims description 3
- 108010025307 buforin II Proteins 0.000 claims description 3
- UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 claims description 3
- 108091008039 hormone receptors Proteins 0.000 claims description 3
- 210000003470 mitochondria Anatomy 0.000 claims description 3
- 108010043655 penetratin Proteins 0.000 claims description 3
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 101150019028 Antp gene Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 108010011110 polyarginine Proteins 0.000 claims description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 abstract description 14
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 abstract description 14
- 238000003384 imaging method Methods 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 6
- 238000012377 drug delivery Methods 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 79
- 239000000243 solution Substances 0.000 description 57
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 46
- 239000002609 medium Substances 0.000 description 46
- 238000002965 ELISA Methods 0.000 description 43
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 40
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 40
- 229960000723 ampicillin Drugs 0.000 description 36
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 35
- 239000006228 supernatant Substances 0.000 description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
- 102000004196 processed proteins & peptides Human genes 0.000 description 34
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 33
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 32
- 238000002835 absorbance Methods 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 28
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 28
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 27
- 239000000203 mixture Substances 0.000 description 25
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 24
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 24
- 238000005406 washing Methods 0.000 description 24
- 229920001817 Agar Polymers 0.000 description 23
- 239000008272 agar Substances 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 23
- 238000004091 panning Methods 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- 241000588724 Escherichia coli Species 0.000 description 20
- 108010067306 Fibronectins Proteins 0.000 description 20
- 102000016359 Fibronectins Human genes 0.000 description 20
- 102000008100 Human Serum Albumin Human genes 0.000 description 20
- 108091006905 Human Serum Albumin Proteins 0.000 description 20
- 239000002202 Polyethylene glycol Substances 0.000 description 18
- 239000000872 buffer Substances 0.000 description 18
- 229920001223 polyethylene glycol Polymers 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 17
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 16
- 238000005119 centrifugation Methods 0.000 description 15
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 14
- 101710176384 Peptide 1 Proteins 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 229930027917 kanamycin Natural products 0.000 description 12
- 229960000318 kanamycin Drugs 0.000 description 12
- 229930182823 kanamycin A Natural products 0.000 description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000002823 phage display Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 108050005238 Collagenase 3 Proteins 0.000 description 8
- 102100027995 Collagenase 3 Human genes 0.000 description 8
- 238000001712 DNA sequencing Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 235000020183 skimmed milk Nutrition 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000004624 confocal microscopy Methods 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 5
- 101710094648 Coat protein Proteins 0.000 description 5
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 101710083689 Probable capsid protein Proteins 0.000 description 5
- 101800001693 R-peptide Proteins 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000000107 tumor biomarker Substances 0.000 description 5
- 102100032187 Androgen receptor Human genes 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- 101150053046 MYD88 gene Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 108010080146 androgen receptors Proteins 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 210000003321 cartilage cell Anatomy 0.000 description 4
- 210000001612 chondrocyte Anatomy 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000000149 penetrating effect Effects 0.000 description 4
- 238000013492 plasmid preparation Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000724791 Filamentous phage Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 229910000859 α-Fe Inorganic materials 0.000 description 3
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 2
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102400000113 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108050009160 DNA polymerase 1 Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010066486 EGF Family of Proteins Proteins 0.000 description 2
- 102000018386 EGF Family of Proteins Human genes 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 101150040383 pel2 gene Proteins 0.000 description 2
- 101150050446 pelB gene Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- DIJNKKIYOHCAPO-UHFFFAOYSA-N 2-benzhydryloxy-n,n-diethylethanamine;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(OCCN(CC)CC)C1=CC=CC=C1 DIJNKKIYOHCAPO-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101000984722 Bos taurus Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000010792 Chromogranin A Human genes 0.000 description 1
- 108010038447 Chromogranin A Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- 102400000242 Dynorphin A(1-17) Human genes 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- NZAFOTBEULLEQB-WDSKDSINSA-N Gly-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN NZAFOTBEULLEQB-WDSKDSINSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101000852255 Homo sapiens Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101100102448 Homo sapiens VCAM1 gene Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010048179 Lypressin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical class C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 101100426589 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) trp-3 gene Proteins 0.000 description 1
- 102100036961 Nuclear mitotic apparatus protein 1 Human genes 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 101100218522 Schizosaccharomyces pombe (strain 972 / ATCC 24843) bpb1 gene Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 101150097457 Vcam1 gene Proteins 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000002819 bacterial display Methods 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 108700021293 carbetocin Proteins 0.000 description 1
- 229960001118 carbetocin Drugs 0.000 description 1
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 108700025485 deslorelin Proteins 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
- 108700032313 elcatonin Proteins 0.000 description 1
- 229960000756 elcatonin Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 108700020746 histrelin Proteins 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003837 lypressin Drugs 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical class C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 108010036112 nuclear matrix protein 22 Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229940072644 pitressin Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 229960002959 sincalide Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- IBKZNJXGCYVTBZ-IDBHZBAZSA-M sodium;1-[3-[2-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]ethyldisulfanyl]propanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCSSCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 IBKZNJXGCYVTBZ-IDBHZBAZSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 1
- 229960002811 ziconotide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a bipodal peptide binder for intracellular target binding and a preparation method thereof.
- Antibodies are immunoglobulin proteins, a type of plasma protein produced by B cells, that specifically inactivate and inactivate antigens by specifically recognizing and binding to specific sites of antigens.
- the specificity and high affinity of these antigen-antibody reactions and the diversity of antibodies that can distinguish tens of millions of antigens have led to the emergence of many types of antibody products, including diagnostics and therapeutics.
- the FDA has approved 21 monoclonal antibodies .
- Antibodies such as Rituximab and Herceptin have been effective in more than 50% of patients who have not responded to any other treatment. Substantially, several studies have used monoclonal antibodies to treat lymphoma and colon cancer. Or successful clinical treatment of breast cancer.
- the overall market size of therapeutic antibodies is estimated to grow at an annual rate of 20%, from $ 10 billion in 2004 to $ 30 billion in 2010.
- the market is expected to grow exponentially.
- the development of new drugs using antibody dispersal is active because the drug development period is short, investment costs are low, and side effects can be easily predicted.
- the antibody is a herbal medicine, the human body is hardly affected, and the half-life in the body is overwhelmingly long compared to low molecular weight drugs, so the patient is friendly.
- monoclonal antibodies in humans are recognized as foreign antigens and can cause severe allergic reactions or hypersensitivity.
- the anti-cancer function of the cloned antibody is produced in a three-phased manner, the production cost is high.
- a wide range of technologies including methods for culturing and purifying antibodies, are protected by various intellectual property rights, and high licensing fees must be paid.
- Antibody-replacement protein is a recombinant protein made to have constant and variable regions like an antibody.
- a small and stable protein is replaced with a random sequence of amino acids to make a library, which is then screened for the target material, thereby providing high affinity and good Substances with specificity can be found.
- avimers and affibodies among antibody replacement proteins have been reported to have a picomol affinity for a target substance. It is reported that these antibody replacement proteins are small and stable and can penetrate deep into cancer cells and generally produce less immune responses.
- antibody replacement proteins There are currently 40 antibody replacement proteins that have been developed. Among them, the antibody replacement proteins that are being commercialized by venture companies and multinational pharmaceutical companies are fibronectin type m domain, lipocalin, LDLR-A domain, crystallin, protein A and ankyrin repeat. (Ankyrin repeat), which uses a protein called BPTI and has a high affinity of several nanomolar to picomolar to the target. Among them, Adnectin, Avimer, and Kunitz domains are currently under FDA clinical trial.
- the present invention focused on peptide-based antibody replacement proteins that are different from antibody replacement proteins using proteins up to now.
- Peptides have been widely used in place of antibody therapeutics due to their proper pharmacokinetics, mass productivity, low toxicity, antigenic inhibition and low production cost compared to antibodies.
- the advantages of peptides as therapeutic drugs are low production costs, high safety and reactivity, relatively low patent royalties, and less exposure to unwanted immune systems, which can inhibit the production of antibodies to the peptides themselves. Modifications are easy and accurate, but most peptides have low affinity and specificity for specific protein levels compared to antibodies, making them unusable for many applications. There are disadvantages.
- the present inventors have tried to develop a peptide material that can be efficiently targeted to intracellular target molecules when treated in vitro, exemplified by intracellular.
- a peptide is randomly coupled to both ends of a structure stabilization site having a relatively rigid peptide backbone, and when the cell membrane penetrating peptide (CPP) is bound to the peptide, intracellular target molecules are bound.
- CPP cell membrane penetrating peptide
- an object of the present invention is to provide a method for preparing intracellular targeting bipodal-peptide binder that specifically binds to intracellular target molecules.
- Another object of the present invention is to provide an intracellular targeting bipodal peptide binder that specifically binds to intracellular target molecules.
- Another object of the present invention is to provide a transformant comprising a vector for expressing intracellular targeting bipodal peptide binder that specifically binds to intracellular target molecules.
- the present invention provides a method for preparing an intracellular targeting bipodal peptide binder that specifically binds to intracellular target molecules, comprising the following steps:
- the invention comprises: (a) parallel, antiparallel or parallel and antiparallel amino acid strands formed with non-covalent bonds between the strands; Structure stabilizing regions; (b) ⁇ and m amino acids each bound to both ends of the structural stabilization site and selected at random; Including target binding region I and target binding region ⁇ ; And (c) an intracellular targeting bipodal peptide binder that specifically binds to intracellular target molecules, including a cell transmembrane peptide (CPP) bound to the structural stabilization site or the target binding site.
- CPP cell transmembrane peptide
- the present inventors sought to develop a peptide material that can be efficiently targeted to intracellular target molecules when treated in vitro, and ex vivo.
- a peptide is randomly coupled to both ends of a structure stabilization site having a relatively rigid peptide backbone, and when the cell membrane penetrating peptide (CPP) is bound to the peptide, intracellular target molecules are bound.
- CPP cell membrane penetrating peptide
- the basic strategy of the present invention is to connect a peptide that is bound to a target at both ends of a rigid peptide backbone.
- the rigid peptide backbone acts to stabilize the overall structure of the bipodal peptide provider and enhances the binding of the target binding site I and the target binding site ⁇ to the target molecule.
- Structural stabilization sites available in the present invention include parallel, antiparallel or parallel and antiparallel amino acid strands, interstrand hydrogen bonds, electrostatic interactions, hydrophobic interactions, van der Waals interactions, pi-pi Protein structural motifs in which non-covalent bonds are formed by interactions, cation-pi interactions, or combinations thereof; hydrogen-bonding, electrostatic interactions, hydrophobic interactions, van der Waals interactions, pi-pi interactions Non-covalent bonds formed by action, cation-pi interaction, or a combination thereof contribute to the rigidity of the structure stabilization site.
- interstrand non-covalent bonds at the structure stabilization site include hydrogen bonding, hydrophobic interaction, van der Waals interaction, pi-pi interaction or a combination thereof ⁇
- a covalent bond to the structured stabilization site.
- the increase in firmness by such covalent bonds is given in consideration of the specificity and affinity of the bipodal peptide binder for the target.
- the amino acid strands of the structure stabilization site are linked by a linker.
- linker as used to refer to the strands refers to the material that connects the strands.
- the turn sequence in ⁇ -hairpin serves as a linker
- a substance connecting two C-terminus of leucine zipper eg , Peptide linkers
- Linkers link parallel, antiparallel or parallel and antiparallel amino acid strands. For example, at least two strands (preferably two strands) arranged in parallel fashion, at least two strands (preferably two strands) arranged in antiparallel fashion, and at least three strands arranged in parallel and antiparallel fashion.
- the linker (preferably three strands) is joined by the linker.
- the linker is a turn sequence or peptide linker.
- the turn sequence is ⁇ -turn, ⁇ -turn, ⁇ -turn, ⁇ -turn or ⁇ —loop (Venkatachalam CM (1968), Biopolymers, 6, 1425-1436; Nemethy G and Print z MP. (1972), Macromolecules, 5, 755-758; Lewis PN et al., (1973), Biochim. Biophys. Acta, 303, 211-229; Toniolo C. (1980) CRC Crit. Rev. Biochem., 9, 1-44; Richardson JS. (1981), Adv. Protein Chem., 34, 167-339; Rose GD et al., (1985), Adv.
- the turn sequence used in the present invention is ⁇ -turn.
- ⁇ -turn When ⁇ -turn is used as the turn sequence, it is preferably a type I, type, type ⁇ , type ⁇ ', type m or type ⁇ turn sequence, more preferably type I, type 1', type ⁇ , type ⁇ 'turn sequence, even more preferably type ⁇ or Type ⁇ 'turn sequence, most preferably the type ⁇ turn sequence (BL Sibanda et al., J. Mo J. Biol., 1989, 206, 4, 759-777; BL Sibanda et al., Methods Enzymol. , 1991, 202, 59-82).
- the turn sequence in the present invention is H. Jane Dyson et al. , Eur. J. Biochem. 255: 462-471 (1998), which is incorporated herein by reference.
- Available for the turn sequence include the following amino acid sequences: X—Pro-Gly-Glu- Val; Ala-X-Gly-Glu-Val (X is selected from 20 amino acids).
- the peptide linker connects two strands arranged in a parallel manner or two strands arranged in an antiparallel manner. desirable.
- Peptide linkers can be used in any known in the art.
- the sequence of a suitable peptide linker may be selected in consideration of the following factors: (a) the ability to be applied to flexible extended conformation; (b) the ability not to create secondary structures that interact with biological target molecules; And (c) the absence of hydrophobic residues or residues with charges that interact with the biological target molecule.
- Preferred peptide linkers include Gly, Asn and Ser residues. Other neutral amino acids such as Thr and Ala can also be included in the linker sequence.
- Suitable amino acid sequences for linkers are Maratea et al., Gene 40: 39-46 (1985); Murphy et al. , Proc. Natl. Acad Sci. USA 83: 8258-8562 (1986); US Pat. Nos. 4,935,233, 4,751,180, and 5,990,275.
- the peptide linker sequence may consist of 1-50 amino acid residues.
- the structure stabilization site is a hairpin, ⁇ -hairpin, beta-turn, a linker-linked ⁇ -sheet or a linker-linked leucine zipper, and more preferably, the structure stabilization site is ⁇ -hairpin. Or ⁇ -sheets linked by linkers, most preferably ⁇ -hairpins.
- ⁇ -hairpin refers to two ⁇ Containing means liver _ simple protein motif, these two ⁇ strands are antiparallel to each other Indicates an alignment. In this ⁇ -hairpin the two ⁇ strands are generally linked by turn sequences.
- the turn sequence applied to the ⁇ -hairpin is a type I, type ⁇ , type ⁇ , type ⁇ ', type ⁇ or type ⁇ turn sequence, more preferably type I, type I', type ⁇ , type ⁇ 'turn sequence, even more preferably a type ⁇ or type ⁇ ' turn sequence, and most preferably a type ⁇ turn sequence.
- X-Pro-Gly-Glu-Val Or a turn sequence represented by Ala—X-Gly-Glu—Val (X is selected from 20 amino acids) can also be used for ⁇ -hairpins.
- the type I turn sequence is Asp-Asp-Ala- Thr-Lys-Thr
- the type ⁇ turn sequence is Glu—Asn-Gly-Lys
- the type ⁇ turn sequence is X-Pro -Gly-Glu-Val
- Ala-X-Gly-Glu-Val X is selected from 20 amino acids
- the type ⁇ 'turn sequence is Glu-Gly-Asn-Lys or Glu-D-Pro-Asn -Lys.
- Peptides with ⁇ -hairpin formulations are well known in the art. Tryptophan zipper, disclosed in, for example, US Pat. No. 6,914,123 and Andrea G. Cochran et al., PNAS, 98 (10): 5578-5583, template-fixed ⁇ - disclosed in WO 2005/047503. Hairpin Memetic, ⁇ -hairpin variants disclosed in US Pat. No. 5,807,979 are well known.
- peptides having a ⁇ -hairpin conformation include Smith & Regan (1995) Science 270: 980-982; Chou & Fassman (1978) Annu. Rev. Biochem.
- a tryptophan zipper is used.
- the tryptophan zipper to be groomed in the present invention is represented by the following general formula (I):
- Xi is Ser or Gly-Glu
- X 2 and X ' 2 are independently of each other Thr, His, Val, He, Phe or Tyr
- X 3 is Trp or Tyr
- X 7 is Lys or Thr—Glu.
- 3 ⁇ 4 is ser or Gly-Glu
- X 2 and X'2 are independently of each other Thr, His or Val
- 3 ⁇ 4 is Trp or Tyr
- X4 is Type I, Type 1 ', Type ⁇ or type ⁇ ' turn sequence
- 3 ⁇ 4 is Trp or Phe
- 3 ⁇ 4 is Trp or Val
- X 7 is Lys or Thr-Glu.
- 3 ⁇ 4 is Ser or Gly-Glu
- 3 ⁇ 4 and X'2 are independently of each other Thr, His or Val
- 3 ⁇ 4 is Trp
- X4 is type I, type 1 ', type ⁇ or type ⁇ ′ turn sequence
- 3 ⁇ 4 is Trp
- 3 ⁇ 4 is Trp
- X 7 is Lys or Thr-Glu.
- Thr is 3 ⁇ 4 is Trp, is type ⁇ or type ⁇ 'turn sequence, 3 ⁇ 4 is Trp, 3 ⁇ 4 is Trp and X 7 is Lys.
- 3 ⁇ 4 is Ser, 3 ⁇ 4 and X'2 are Thr, 3 ⁇ 4 is Trp, is type ⁇ turn sequence (ENGK) or type ⁇ 'turn sequence (EGNK), 3 ⁇ 4 is Trp 3 ⁇ 4 is Trp and X 7 is Lys.
- ENGK type ⁇ turn sequence
- EGNK type ⁇ 'turn sequence
- ⁇ -hairpin peptides usable as structural stabilization sites in the present invention are peptides derived from B1 domainin of protein G, ie GB1 peptides.
- the structural stabilization site is preferably represented by the following general formula:
- Xi is Arg, Gly-Glu or Lys-Lys
- 3 ⁇ 4 is Gin or Thr
- 3 ⁇ 4 is type I, type r, type ⁇ , type ⁇ 'or type m or type nr turn sequence, is Gin, Thr-Glu Or Gln-Glu.
- Xi is Gly-Glu or Lys-Lys
- X 2 is type I, type ⁇ , type ⁇ , type ⁇ 'or type m or type ⁇ turn sequence
- 3 ⁇ 4 is Thr-Glu or Gln-Glu.
- Exemplary amino acid sequences of GB1 ⁇ -hairpins suitable for the present invention are described in SEQ ID NO: 4 and 14 to 15 sequences.
- ⁇ -hairpin peptides usable as structural stabilization sites in the present invention are HP peptides.
- the structural stabilization site is preferably represented by the following general formula m:
- Xi is Lys or Lys-Lys
- X 2 is Trp or Tyr
- 3 ⁇ 4 is Val or Thr
- 3 ⁇ 4 is type I, type ⁇ , type ⁇ , type ⁇ 'or type ⁇ or type ⁇ turn sequence
- 3 ⁇ 4 is Trp or Ala
- 3 ⁇ 4 is Trp or Val
- X 7 is Glu or Gln-Glu.
- Another ⁇ -hairpin peptide that can be used as the structural stabilization site in the present invention is represented by the following general formula IV:
- X 3 ⁇ 4 is Lys-Thr or Gly
- X 2 is Trp or Tyr
- X 3 is Type I ⁇ Type 1 ', Type ⁇ , Type ⁇ ' or Type m or Type ⁇ turn sequence and is Thr-Glu or Gly .
- Exemplary amino acid sequences of the ⁇ -hairpins of Formulas III and IV are described in SEQ ID NOs: 11-12, 15, and 16-19.
- a hairpin (alpha-hairpin, beta-hairpin, gamma-hairpin, ⁇ -hairpin, etc.) may be used as the structural stabilization site.
- beta-turns may be used as structural stabilization sites.
- a ⁇ -sheet connected by a linker may be used as the structure stabilization site.
- two amino acid strands, which are parallel or antiparallel, preferably antiparallel, are in an extended form, and hydrogen bonds are formed between the amino acid strands.
- ⁇ -sheet structure two adjacent ends of two amino acid strands are connected by a linker.
- linker various turn-sequences or peptide linkers described above may be used. If the turn-sequence is used as a linker, the -turn sequence is most preferred.
- leucine zippers or leucine zippers linked by linkers may be used as structural stabilization sites.
- Leucine zippers are conservative peptide domains that cause parallel dimerization of two ⁇ -chains and are generally dimerized domains found in proteins involved in gene expression ("Leucine scissors". Glossary of Biochemistry and Molecular Biology ( Revised) (1997) Ed. David M. Gick. London: Portland Press; Landschulz WH, et al. (1988) Science 240: 1759-1764).
- Leucine zippers generally comprise a heptad repeat sequence, with the leucine residues located at the fourth or fifth.
- Use of the present invention 1_ specific examples of leucine branch 3 ⁇ 4 is described in SEQ ID NO: 39 sequence.
- Each half of the leucine zipper consists of short ⁇ -chains with direct leucine contact between the ⁇ -chains.
- the leucine zipper in the transcription factor generally consists of a hydrophobic leucine zipper site and a basic site (site that interacts with the main groove of the DNA molecule). When the leucine zipper is used in the present invention, the basic site is not necessarily required.
- two adjacent ends of two amino acid strands may be linked by a linker.
- a linker various turn-sequences or peptide linkers described above may be used, and preferably, a peptide linker that does not affect the structure of the leucine zipper is used.
- Random amino acid sequences are coupled to both ends of the above-described structural stabilization site.
- the random amino acid sequence forms the target binding site I and the target binding site ⁇ .
- One of the greatest features of the present invention is to prepare a peptide binder in a bipodal manner by connecting the target binding site I and the target binding site ⁇ at both ends of the structure stabilization site.
- Target binding site I and target binding site ⁇ bind to the target cooperatively with each other, thereby greatly increasing the affinity for the target.
- the amino acid number n of the target binding site I is not particularly limited, preferably an integer of 2-100, more preferably an integer of 2-50, even more preferably an integer of 2-20, most preferably It is an integer of 3-10.
- the amino acid number m of the target binding site ⁇ is not particularly limited, preferably an integer of 2-100, more preferably an integer of 2-50, even more preferably an integer of 2-20, most preferably It is an integer of 3-10.
- the target binding site I and the target binding site ⁇ may each contain different or the same number of amino acid residues.
- the target binding site I and the target binding site ⁇ may include different or identical amino acid sequences, and preferably include different amino acid sequences from each other.
- the amino acid sequence included in the target binding site I and / or the target binding site ⁇ is a linear amino acid sequence or a cyclic amino acid sequence.
- at least one amino acid residue of the amino acid sequence included in the target binding site I and / or binding site ⁇ Acetyl group, fluorenyl methoxy carbonyl group, formyl group, palmitoyl group myristyl group, stearyl group or polyethylene glycol (PEG).
- the bipodal peptide binder of the present invention bound to a biological target molecule can be used for the regulation of physiological responses in vivo, detection of in vivo substances, in vivo molecular imaging, in vitro cell imaging and drug delivery targeting. It can also be used as an escort molecule.
- a functional molecule is additionally bound to the structure stabilization site, the target binding site I or the target binding site ⁇ (more preferably, the structure stabilization site, even more preferably the linker of the structure stabilization site) have.
- functional molecules include, but are not limited to, labels, chemicals, biopharmaceuticals, cell transmembrane peptides (CPPs) or nanoparticles that generate detectable signals.
- Labels that generate the detectable signal include T1 contrast material (eg Gd chelate compound), T2 contrast material (eg superparamagnetic material (eg magnetite, Fe 3 0 4 , Y-Fe 2 0 3) manganese ferrite, cobalt Ferrites and nickel ferrites)), radioisotopes (e.g., 15 0, 13 N, P 32 , S 35 , 44 Sc, 45 Ti, 118 I, 136 La, 198 T1, 200 T1, 205 Bi and 206 Bi) , Including but not limited to fluorescent materials (fluorescein, phycoerythrin, rhodamine, lissamine, and Cy3 and Cy5), chemiluminescence groups, magnetic particles, mass labels or electron-dense particles It doesn't happen.
- T1 contrast material eg Gd chelate compound
- T2 contrast material eg superparamagnetic material (eg magnetite, Fe 3 0 4 , Y-Fe 2 0
- the chemicals include, for example, anti-inflammatory drugs, analgesics, anti-arthritis agents, antispasmodics, antidepressants, antipsychotics, neurostabilizers, anti-anxiety drugs, antagonists, antiparkin's disease drugs, cholinergic agonists, anticancer agents, antiangiogenic agents, Immunosuppressants, antivirals, antibiotics, appetite suppressants, analgesics, anticholiners, antihistamines, antimigraine, hormones, coronary, cerebrovascular or peripheral vasodilators, contraceptives, antithrombotics, diuretics, antihypertensives, cardiovascular diseases , Cosmetic ingredients (eg, anti-wrinkle agent, anti-aging agent and skin lightening agent) and the like, but are not limited thereto.
- Cosmetic ingredients eg, anti-wrinkle agent, anti-aging agent and skin lightening agent
- the biopharmaceuticals include insulin, IGF-K insulin-like growth factor 1), growth hormone, erythropoietin, G-CSFs (granulocyte-colony stimulating factors), GM-CSFs (granulocyte / macrophage—colony stimulating factors), Interferon alpha, interferon beta, interferon gamma, interleukin-1 alpha and beta, interleukin-3, interleukin-4, interleukin-6, interleukin-2, EGFs (epidermal growth factors), calcitonin, adrenocorticotropic hormone (ACTH), TNF (tumor necrosis factor), atobisban, buserelin, cetrorelix, deslorelin, desmopressin, dynorphin A ) (1-13), elcatonin, eleidosin, epitif ibatide, GHRH— 11 (growth hormone releasing hormone ⁇ II), gonadorelin, gonsere Gos
- Target binding site I and / or target binding site ⁇ may comprise amino acid sequences that bind to various targets.
- Targetable by the bipodal peptide binders of the present invention include biochemicals, peptides, polypeptides, nucleic acids, carbohydrates, lipids, biological targets such as cells and tissues, compounds, metals or nonmetallic materials, preferably It is a biological target.
- the biological target to which the target binding site binds is preferably a biochemical, a peptide, a polypeptide, a glycoprotein, a nucleic acid, a carbohydrate, a proteoglycan, a lipid or a glycolipid.
- the biochemicals to which the target binding site binds include a variety of in vivo metabolites (eg, AT ⁇ NADH, NADPH, carbohydrate metabolites, lipid metabolites ' and amino acid metabolites).
- exemplary peptides or polypeptides to which a target binding site binds include enzymes, ligands, receptors, biomarkers, hormones, transcription factors, growth factors, immunoglobulins, signaling proteins, binding proteins, ion channels, antigens, adhesion proteins, structural proteins. , Regulatory proteins, toxin proteins, cytokines and hematological factors. More specifically, the target of the bipodal peptide binder is
- Fibronectin extra domain B VEGFCvascular endothel ial growth factor (VEGFR), vascular endothel ial growth factor receptor (VEGFR), VCAMK vascular cell adhesion molecule— 1), nicotinic acetylcholine receptor (nAchR), human serum albumin (HSA), MyD88, Epi dermal Growth Factor Receptor (EGFR), HER2 / neu, CD20, CD33, CD52, Epithelial Cell Adhesion Molecule (EpCAM), TNF-a (Tumor Necrosis Factor—a), IgE (Immunoglobulin E), CD11A (a- chain of lymphocyte funct ion ⁇ associated antigen 1), CD3, CD25, Glycoprotein Ilb / IIIa, integrin, alpha-fetoprotein (AFP), (beta2-microglobul in), and B ladder Tumor (BTA)
- VEGFCvascular endothel ial growth factor VEGFC
- NMP22 Cancer Antigen 125
- Cancer Antigen 15-3 Calcitonin
- Carcinoembryonic Antigen Chromogranin A
- Estrogen Receptor Progesterone Receptor
- Human Chorionic Gonadotropin Neuron-Specific Enolase
- PAP Prostate-Specific Antigen
- Thyroglobul Thyroglobul in, but are not limited thereto.
- Exemplary nucleic acid molecules to which the target binding site binds include, but are not limited to, gDNA, mRNA, cDNA, ribosomal RNA (rRNA), ribosomal DNA (rDNA), and tRNA.
- Exemplary carbohydrates to which the target binding site binds are intracellular carbohydrates, including but not limited to monosaccharides, disaccharides, trisaccharides, and polysaccharides.
- Exemplary lipids to which the target binding site binds include, but are not limited to, fatty acids, triacylglies, sphingolipids, gangliosides, and cholesterol.
- the bipodal peptides of the present invention can bind to biomolecules (eg proteins) in cells to modulate the activity of the biomolecules.
- biomolecules eg proteins
- the cell transmembrane peptide is bound to a structural stabilization site.
- the CPP includes various CPPs known in the art and include, for example, HIV-1 Tat protein, oligoarginine, ANTP peptide, HSV VP22 transcriptional regulator protein, MTS peptide derived from vFGF, Penetratin, Transport an, Pep -1 peptide, Pep-7 peptide, Buforin II, model amphiphatic peptide (MAP), k-FGF, Ku 70, pVEC, SynBl or HN-1.
- the CPP covalently binds the lysine residue of the loop portion at the structural stabilization site of the bipodal peptide.
- bipodal peptide binders bound to CPP enter the cell to bind to and regulate (eg, inhibit) the activity.
- Example 19 below shows specific examples of targeting of intracellular proteins of bipodal peptide binders.
- MyD88 is well known as an intracellular protein that interacts with TLR 4, interleukin 1 receptor, RACl, IRAK2 and IRAKI.
- the CPP-bipodal peptide binder having binding specificity to MyD88 enters cells and inhibits the function of MyD88, thereby effectively blocking the expression of MMP-13.
- the intracellular target molecule is a cytoplasmic region, a cytoplasmic protein, an organelled protein, a nuclear protein or an intracellular nucleic acid molecule or an intracellular chemical of a cell membrane protein, more preferably the cell My target molecules are cancer-associated proteins, apoptosis-related proteins, receptor cytoplasmic domains, G-protein coupled receptor cytoplasmic domains, hormones, hormone receptors, enzymes, Histone deacetylase (HDAC), immune-related proteins, Toll-like receptors Intracellular proteins involved in signaling, proteins in blood coagulation, proteins in ERCendoplasmic reticulum, proteins in mitochondria or nuclear proteins.
- the cell My target molecules are cancer-associated proteins, apoptosis-related proteins, receptor cytoplasmic domains, G-protein coupled receptor cytoplasmic domains, hormones, hormone receptors, enzymes, Histone deacetylase (HDAC), immune-related proteins, Toll-like receptors
- the bipodal peptide binder of the present invention typically has a construct of one strand-linker-structural stabilization site of the target binding site I-structure stabilization site, and the other strand-target binding site ⁇ -C ′′.
- a structure influence inhibiting region is provided that blocks the mutual structural effects between the target binding site and the structure stabilization site.
- ⁇ is amino acids that are relatively free to rotate ⁇ and ⁇ in the peptide molecule.
- ⁇ is amino acids that are relatively free to rotate ⁇ and ⁇ in the peptide molecule.
- Amino acids that are relatively free of ⁇ are glycine, alanine and serine.
- 1-10 amino acid residues preferably 1-8, and more preferably 1-3 amino acid residues may be located in the structure influence inhibitory site.
- the bipodal peptide binder will have a random sequence, indicating that there is no sequence preference or no designated (or fixed) amino acid residue at any position of target binding site I and / or target binding site ⁇ . it means.
- a library of bipodal peptide binders can be used in a split-synthesis method (Lam et al. (1991) Nature 354: 82; WO 92/00091) carried out on a solid support (eg, polystyrene or polyacrylamide resin). Can be built accordingly.
- the library of bipodal peptide binders is constructed in a cell surface display manner (eg phage display, bacterial display or yeast display).
- the library of bipodal peptide binders may be prepared through a display method based on plasmids, bacteriophages, phagemids, yeasts, bacteria, mRNA or ribosomes.
- Phage display is a technique for displaying various polypeptides in the form of proteins fused to coat proteins on the surface of the phage (Scott, J. K. and Smith,
- Phageimide may be used for the fiji display.
- Phageimide is a plasmid vector with one copy of the bacterial origin of replication (eg, ColEl) and the intergenic site of the bacteriophage. DNA fragments cloned in this phagemid are propagated like polamide.
- a preferred embodiment of the present invention comprises the following steps: (i) Phage coat protein (e.g., filamentous phage gene ⁇ or gene ⁇ , such as M13) A fusion gene in which a gene encoding a coat protein) and a gene encoding a bipodal peptide binder are fused; And constructing a library of expression vectors comprising transcriptional regulatory sequences (eg, lac promoters) operably linked to the fusion gene; ( ⁇ ) introducing the expression vector library into a suitable host cell; (iii) culturing the host cell to form recombinant phage or phagemid virus particles so that the fusion protein is displayed on the surface; (iv) contacting a biological target molecule with the viral particle to bind the particle to the target molecule; And (V) separating particles not bound to the target molecule.
- Phage coat protein e.g., filamentous phage gene ⁇ or gene ⁇ , such as M13
- the method of producing an expression vector comprising a bipodal peptide binder gene may be carried out according to methods known in the art.
- known phagemids or phage vectors eg, pIGT2, fUSE5, fAFFl, fd-CATl, m663, fdtetDOG, pHENl, pComb3, pComb8, pCANTAB 5E (Pharmacia), LamdaSur f Zap, pIF4, PM48, PM52,
- Expression vectors can be prepared by inserting a bipodal peptide binder gene into PM54, fdH and p8V5).
- phage display methods are performed using filamentous phage, lambda phage display (W095 / 34683; US Pat. No. 5,627,024), T4 phage display (Ren et al. (1998) Gene 215: 439; Zhu (1997) CAN 33: 534) and T7 phage display (US Pat. No. 5,766,905) also build a library of bipodal peptide binders. It can be used to.
- Suitable hosts for the present invention are gram negative bacterial cells such as E. coli, and suitable E. coli hosts include JM101, E. coli K12 strain 294, E. coli strain W3110 and E. coli XL-lBlue (Stratagene). Including, but not limited to. Host cells are preferably prepared as competent cells prior to transformation (Sambrook, J. et al., Molecular Cloning. A Laboratory Manual, 3rd ed. Cold Spring Harbor Press (2001)).
- Selection of transformed cells is generally carried out by culturing in a medium containing antibiotics (eg tetracycline and ampicillin). Selected transformed cells are further cultured in the presence of helper phage to generate recombinant phage or phagemid virus particles.
- Suitable helper phage phages include, but are not limited to, Ex helper phages, M13-K07, M13-VCS, and R408.
- bipodal peptide binders of the present invention are described in SEQ ID NO: 20-38 and 40-41.
- the invention provides a nucleic acid molecule encoding the intracellular targeting bipodal peptide binder described above.
- the present invention provides a vector for expression of a bipodal peptide binder comprising a nucleic acid molecule encoding an intracellular targeting bipodal peptide binder.
- the present invention provides a transformant comprising a vector for expression of the intracellular targeting bipodal peptide binder.
- nucleic acid molecule is meant to encompass DNA (gDNA and cDNA) and RNA molecules inclusively, and the nucleotides that are the basic building blocks of nucleic acid molecules are naturally modified nucleotides, as well as modified sugar or base sites. Analogues (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews, 90: 543-584 (1990)).
- the vector of the present invention is a strong promoter (for example, tac promoter, lac promoter, / adJV5 promoter, which is capable of promoting transcription to the nucleic acid molecule in addition to the nucleic acid molecule encoding the bipodal peptide binder, Ipp promoter, p L x promoter, p / promoter, ra (S promoter, amp promoter, recA promoter, SP6 promoter, trp promoter and T7 promoter, etc.), ribosomal binding site and transcription / detox termination sequence for initiation of translation It includes.
- a strong promoter for example, tac promoter, lac promoter, / adJV5 promoter, which is capable of promoting transcription to the nucleic acid molecule in addition to the nucleic acid molecule encoding the bipodal peptide binder, Ipp promoter, p L x promoter, p / promoter, ra (S promoter, amp promoter, recA promote
- the vector of the invention may further comprise a signal sequence (eg pelB) on the 5'-direction of the nucleic acid molecule encoding the bipodal peptide binder.
- the vector of the present invention further comprises a tagging sequence (eg, myc tag) for confirming that the bipodal peptide binder is well expressed on the surface of the phage.
- the vector of the invention comprises a phage coat protein, preferably a gene encoding the gene m or gene vm coat protein of filamentous phage such as M13.
- the vector of the present invention comprises an origin of replication of bacteria (eg ColEl) and / or a bacteriophage.
- the vector of the present invention may include an antibiotic resistance gene commonly used in the art as a selection marker, for example, ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neo Genes against resistance to mycin and tetracycline.
- the transformants of the present invention are preferably Gram-negative bacterial cells such as E. coli, and suitable E. coli hosts are JM101, E. coli K12 strain 294, E. coli strain W3110 and E. coli XL-lBlue (Stratagene ), But is not limited thereto.
- the method of carrying the vector of the present invention into a host cell may be performed by CaCl 2 method (Cohen, SN et al., Proc. Natl. Acac. Sci. USA, 9: 2110-2114 (1973)), one method (Cohen, SN et al., Proc. Natl. Acac. Sci. USA, 9: 2110-2114 (1973); and Hanahan, D., J. Mol. Biol., 166: 557-580 (1983)) and electroporation methods (US Pat. Nos. 5,186,800, 5,422,272, 5,750,373) and the like.
- the bipodal peptide binders of the present invention exhibit very low levels (eg, nM levels) of values (dissociation constants) to provide peptides with very high affinity to biological target molecules.
- the bipodal peptide binder exhibits about 10 2 -10 5 times (preferably about 10 3 -10 4 times) high affinity as compared to the binder made in the monopodal manner.
- the bipodal peptide binder of the present invention not only has a use as a medicament, but also can be used for the detection of intracellular substances, in vivo molecular imaging, in vitro cell imaging and drug delivery, and also as an escort molecule. Can be.
- the present invention provides intracellular targeting bipodal peptide binders with novel constructs.
- the intracellular targeting bipodal peptide binder of the present invention thus exhibits very low levels (e.g., nM levels) of K D values (dissociation constants), resulting in very high affinity to the target.
- the intracellular targeting bipodal peptide binder of the present invention not only has a use as a medicament, but also can be used for the detection of intracellular substances, in vivo molecular imaging, in vitro cell imaging and drug delivery, It can also be used as an escort molecule.
- La shows a schematic diagram of a bipodal-peptide binder comprising ⁇ -hairpin as a structural stabilization site.
- FIG. Lb shows a schematic diagram of a bipodal-peptide binder comprising ⁇ -sheets linked by linkers as structural stabilization sites.
- FIG. Lc shows a schematic diagram of a bipodal peptide binder comprising leucine zippers linked by linkers as structural stabilization sites.
- Figure ID shows a schematic of a bipodal-peptide binder comprising a leucine-rich motif linked by a linker as a structural stabilization site.
- the pelB signal sequence myc tag
- the lac promoter was used as a promoter.
- FIG. 3 shows the biopanning results of ED-B, straptavidin and BSA for input phage during pyronectin ED-B biopanning.
- FIG. 4 shows ELISA results for ED-B and BSA of 60 recombinant phages recovered in the third stage of biopanning of bipodal peptide binder library during pyronectin ED-B biopanning.
- Figure 5a is a result of measuring the affinity of a specific bipodal peptide binder that binds to the pyronectin ED-B protein.
- Figure 5b is the result of measuring the affinity of a specific bipodal peptide binder that binds to VEGF.
- Figure 5c is the result of measuring the affinity of a specific bipodal peptide binder that binds to VCAMl.
- Figure 5d is a result of measuring the affinity of a specific bipodal peptide binder binding to nAchR (Nicotinic acetylcholine receptor).
- Figure 5e is the result of measuring the affinity of a specific bipodal peptide binder that binds to HSAOluman Serum Albumin).
- Figure 6a is a result of measuring the absorbance of the recombinant phage having a bipodal peptide binder ELISA for a number of proteins for specificity test for pyronectin ED-B. From the left bar, results for straptavidin, ED-B, acetylcholine al, BSA, VCAM, TNF- ⁇ , thrombin, myoglobulin, lysozyme and bispartin.
- Figure 6b is a result of measuring the absorbance of the recombinant phage having a bipodal peptide binder ELISA for a variety of proteins to test for specificity for VEGF. '
- Figure 6c is a result of measuring the absorbance of the recombinant phage having a bipodal peptide binder ELISA for a variety of proteins for specificity test for VCAM1.
- Figure 6d is a result of measuring the absorbance of the recombinant phage having a bipodal peptide binder ELISA for a number of proteins to test the specificity for the nAchR fragment peptide.
- Figure 6e is a result of measuring the hop brightness by performing an ELISA for a number of proteins recombinant phage having a bipodal peptide binder to test the specificity for HSA.
- Figure 6f is a result of measuring the absorbance of the recombinant phage having a bipodal peptide binder ELISA for a variety of proteins to test for specificity for MyD88.
- 7 is a result of measuring the affinity for the demonstration of the synergistic effect of the bipodal temptide binder.
- 8 is a result of measuring the affinity of the bipodal peptide binder by replacing the structural stabilization site with a variety of ⁇ -hairpin motifs instead of tryptophan zipper in the bipodal peptide binder.
- bipodal peptide binders specific for cancer biomarker fibronectin ED-B. Over time, it appears that bipodal peptide binders accumulate in cancer. When the individual organs are separated and measured for fluorescence, they also accumulate in the cancer.
- 11 is a result showing the effect of the intracellular targeting bipodal peptide binder to inhibit the activity of MyD88 present in the cell.
- Figure 12a is a result of measuring the absorbance of the recombinant phage having a bipodal peptide binder ELISA for a variety of proteins for specificity test for AR-DBD.
- FIG. 12B shows ELISA results of AR-DBD of recombinant phage recovered from biopanning of bipodal peptide binder library during Androgen receptor DNA binding domain (AR-DBD) biopanning.
- FIG. 13A shows ELISA results for STAT3 of recombinant phage recovered from biopanning of a bipodal peptide binder library during STAT3 biopanning.
- Figure 13b and Figure 13c is a result of measuring the absorbance of the recombinant phage having a bipodal peptide binder ELISA for a variety of proteins to test for specificity for STAT3.
- 13B is an experimental result for Peptide KQAYYIP GSWTWENGKWTWKG LWGPEF)
- FIG. 13C is an experimental result for Peptide2 (HGFQWP GSWTWENGKWTWKG AYQFLK).
- Figure 13d is the result of measuring the affinity of a specific bipodal peptide binder that binds to STAT3.
- FIG. 13E is an image showing cell delivery capacity specific for STAT3 of a bipodal peptide binder in which 01igo-9 R peptide is bound to a loop.
- FIG. 13F is an image showing the cell delivery capacity of igo-specific R-binding peptide bound to C-terminus of 01igo-9 R peptide.
- Figure 13g is an experimental result showing the activity inhibiting ability of the bipodal peptide binder specific for STAT3 present in the cells.
- Figure 14 is an image showing the cell delivery capacity of the bipodal peptide binder OIigo-9 R peptide to the loop specific for AR-DBD.
- Beta-Fl TOTATGCGGCCCAGCTGGCC (NNK) 6 GGATCTTGGACATGGGAAAACGGAAM-3 '
- Beta-Bl 5'-TOTATGCGGCCCAGCTGGCC (NNK) 6 GGATCTTGGACATGGGAAAACGGAAM-3 '
- N is A, T, G or C; K is G or T; M is C or A.
- Beta-Fl 4 ⁇ , Beta-Bl 4 yM, 2.5 mM dNTP mixture 4 ⁇ , ExTaq DNA polymerase 1 / ⁇ (Takara, Seoul, Korea), and 5 ⁇ of lOxPCR buffer were mixed. A total of 25 mixtures containing distilled water were prepared.
- E.col i XL1 BLUE cells (American Type Culture Collection, Manassas, USA) were plated on LB agar-plates. After the inoculating colonies grown in an agar plate medium in LB medium with 5 heunhap at 37 ° C at a rate of 200 rpm and incubated for one day. Cultured 10 cells were inoculated in 2 LB medium and cultured in the same manner until the absorbance was 0.3-0.4 at a wavelength of 600 nm. The incubated flask was left on ice for 30 minutes, then centrifuged at 4 ° C. at 4,000 ⁇ g for 20 minutes to remove all supernatants except the sunk cells and suspended in 1 sterile sterile distilled water.
- Electroporation was performed by dispensing 25 phagemid vectors 12 / g and bi ⁇ dal peptide binders into 100 ⁇ which linked 2.9 / g insert DNA. Melting competent cells on ice and connecting 200 ⁇ competent cells. After mixing with solution ⁇ , it was placed in a 0.2 cm cuvette prepared for cooling and placed on ice for 1 minute. The electroporator (BioRad, Hercules, CA) was programmed at 200 ⁇ at 25 uF and 2.5 kV and the prepared cuvette was drained and placed in an electroporator and pilsed (time constant 4.5-5 msec).
- the cells were placed in 1 l LB liquid medium containing 20 mM glucose prepared at 37 ° C., and a total of 25 ⁇ cells obtained were transferred to a 100 ra ⁇ tube. After incubation at 200 rpm at 37 ° C. for one hour, 10 ⁇ was diluted and plated in ampicillin agar medium to determine the number of libraries. The remaining cells were put in 1 LB of 20 mM glucose and 50 ⁇ g / mi 0 kpicillin and incubated at 30 ° C for one day. Centrifugation at 4 ° C.
- Recombinant phage was produced in a bipodal peptide binder library stored at -80 ° C.
- Ampicillin LB liquid medium of 100 to 500 flask insert the glucose of 50 and 20 mM, in the library 1 ⁇ 37 ° C for one hour by adding stored at -80 ° C heunhap at a rate of 150 rpm and incubated 1 10 11 pfu of Ex helper phage (Ig therapy, Chuncheon, Korea) was added and cultured under the same conditions for another hour. The supernatant was removed by centrifugation at l, 000Xg for 10 minutes and ampicillin ( Recombinant phages were produced by incubating for one day with 100 LB liquid medium containing 50 ig / mi) and kanamycin (25 / g / m «).
- VEGF vascular endothelial growth factor
- VCAM1 vascular cell adhes i on molecule one 1
- Nicotinic acetylcholine receptor nAchR
- HSA human serum albumin
- MyD88 was prepared as follows.
- TCATAGTCMTGCCCGGCTCCAGCCCTGTG-3 ' was synthesized and combined with EDB-F1 20 pmol, EDB-B1 20 pmol, 2.5 mM dNTP mixture 4 ⁇ , ExTaq DNA polymerase 1 ⁇ (10 U) and 10XPCR buffer 5 ⁇ in total. The mixed solution to which distilled water was added was made.
- the common hapaek PCR reaction a by (5 minutes at 94 ° C, 30 cycles at 55 ° C 30 sec, 1 min and 30 sec at 94 ° C at 72 ° C) and then made to EDB insert using the PCR purification kit Purification by The EDB insert gene and the pET28b vector were subjected to restriction enzymes to link the EDB insert gene to the pET28b vector (Novagen). About 2 / g of insert DNA was reacted with Ba HKWB, Ipswich) and y1 ⁇ 2fe / (NEB, Ipswich) for 4 hours, and then purified using a PCR purification kit.
- the pIGT2 phagemid vector of about 2 was reacted with BamHI and Ndel for 3 hours, and then CIAP was added and reacted for 1 hour, followed by purification using a PCR purification kit. Add them with a molar ratio of about 1: 3 to the vector and insert, connect them for 10 hours at 18 ° C using T4 DNA ligase (Bioneer, Dae j eon, Korea), and attach to XL-1 competent cells. After transformation, they were plated in agar medium containing kanamycin.
- VEGF-Fl 5'-ATAGMTTCGCACCCATGGCAGAA-3 '
- VEGF_B1 5' - ⁇ (; ⁇ 0 ⁇ € 0 ⁇ ( ⁇ ⁇ 0 ⁇ 0 ⁇ 0 ⁇ € -3 ') were synthesized to prepare VEGF-F1 20 pmol, VEGF-B1 20 mM dNTP mixture 4 ⁇ , ExTaq DNA
- the polymerase 1 ⁇ (10 U) and 10XPCR buffer 5 were mixed to prepare a mixture solution in which distilled water was added to a total of 50 ⁇ .
- the common hapaek PCR reaction a by (5 minutes at 94 ° C, 30 cycles at 55 ° C 30 sec, 1 min and 30 sec at 94 ° C at 72 ° C) and then made to VEGF inserts using the PCR purification kit Purification by The VEGF insert gene and the pET32a vector were subjected to restriction enzymes to link the VEGF insert gene to the pET32a vector (Novagen). Approximately 2 / g of insert DNA was reacted for 4 hours with ⁇ ⁇ ? / ( ⁇ , Ipswich) and HindIlKW &, Ipswich) and purified using a PCR purification kit. The molar ratio of vector to insert was about 1: 3.
- T4 DNA ligase (Bioneer Dae j eon, Korea) was used for ligation at 18 ° C for 10 hours, transformed into XL-1 competent cells, and smeared in agar medium containing ampicillin. It was. The colonies grown on agar plate medium were inoculated in 5 LB medium and incubated for one day while mixing at a speed of 200 rpm at 37 ° C., and the plasmids were purified using a plasmid flap kit (GeneAll, Seoul, Korea). Sequencing confirmed whether cloning was successful.
- the Korea Biotechnology Research Institute received the human VCAM1 gene. Restriction enzymes were treated with the VCAM1 insert gene and the pET32a vector to link the VCAM1 insert gene to the pET32a vector. Add them with a molar ratio of about 1: 3 to the vector and insert, connect them for 10 hours at 18 ° C using T4 DNA ligase (Bioneer, Dae j eon, Korea), and attach to XL-1 competent cells. After transformation, the cells were plated in agar medium containing ampicillin.
- IPTG isopropyl- ⁇ -D-kiogalactopyranoside
- the resin was washed with Lysis buffer and then obtained by eluting the N-terminal His-tag ED-B protein using Illution buffer (50 mM sodium phosphate (pH 8.0), 300 mM NaCl and 300 mM imidazole).
- Illution buffer 50 mM sodium phosphate (pH 8.0), 300 mM NaCl and 300 mM imidazole.
- the protein thus obtained was purified by gel filtration using a Superdex75 column (GE Healthcare, United Kingdom) and PBS (pH 7.4) buffer to obtain high-purity ED-B protein.
- Biotin was linked to ED-B protein for biopanning.
- IPTG isopropyl- ⁇ -D-kiogalactopyranoside
- coli was dissolved using a sonicator, and then centrifuged at 15,000 Xg for 1 hour to allow the supernatant to be Ni-NTA affinity resin (Elpisbio, Dae j eon, Korea). To The resin was washed with Lysis buffer and then obtained by eluting the Trx-VEGF121 protein using Illution buffer (50 mM sodium phosphate (pH 8.0), 300 mM NaCl and 300 mM imidazole). The protein thus obtained was purified by gel filtration using a Superdex75 column (GE Healthcare, United Kingdom) and PBS (pH 7.4) buffer to obtain high purity VEGF-Trx and VCAMl-Trx proteins. VEGF121 was obtained by cutting between VEGF and Trx with thrombin to obtain pure VEGF.
- Illution buffer 50 mM sodium phosphate (pH 8.0), 300 mM NaCl and 300 mM imidazole.
- Illution buffer 50 mM
- HSA was purchased from Genetex Company (Irvine).
- Human MyD88 was purchased from Santa Cruz Biotechnology (sc-4540 WBX California).
- a mixture of the bipodal peptide binder recombinant phage containing solution 800 ⁇ and 10% BSA 200! ⁇ was added to 20 wells that were BSA-coated with straptavidin to remove phages binding to straptavidin and BSA for 1 hour. Placed at 27 ° C. The supernatant was recovered and transferred to 20 wells combined with ED-B and nAchR and left at 27 ° C. for 45 minutes. Remove all 20 wells, wash 15 times with 0.5% PBST, and add phages of 0.2 M glycine / HCKpH 2.2) 1 ⁇ to 50 ⁇ each well for 20 minutes.
- 10 E. coli XL1-BLUE cells were mixed and incubated at 37 ° C for 1 hour at 200 rpm. Ampicillin (50 g / m) and 20 mM glucose were mixed and then 2 ⁇ 10 10 pfu of Ex helper phage was added and incubated at 37 ° C. for 1 hour at 200 rpm.
- the culture was centrifuged with l.OOOXg for 10 minutes, then the supernatant was removed and the precipitated cells were resuspended in 40 ra ⁇ LB liquid medium containing ampicillin (50 g / l) and kanamycin (25 g / mi ⁇ ]. Cultures were incubated for one day at 200 rpm at 30 ° C. Cultures were centrifuged at 4,000 ⁇ g, 20 min and 4 ° C. Supernatant was added to 8 ⁇ 5 ⁇ PEG / NaCl [20% PEG (w). / v) and 15% NaCKw / v)] and then left at 4 ° C. for 1 hour.
- VEGF, VCAMl-trx, HSA and MyD 88 (5 / g /) were placed in 10 wells of 96 well ELISA plates (Corning) at 50 ⁇ , then allowed to stand overnight at 4 ° C, using 2% BSA the next day. After blocking for 2 hours at room temperature, the solution was discarded and washed three times with 0.1% PBST. In addition, the bipodal peptide binder recombinant phage containing solution 800 id and 10% BSA 200 ⁇ was mixed and transferred to 10 wells in which VEGF, VCAMl-Trx, and HSA were combined and left at room temperature for 1 hour.
- Straptavidin was placed in 18 wells with 50 ⁇ each well and 10 g / J> BSA was placed in 9 wells with 50 ⁇ each well and left at 4 ° C. for one day. The following day, only nine wells of 18 wells with strramtadine were washed three times with 0.13 ⁇ 4 PBST (tween-20), and biotin ED-BC10 «g / m £) was added and left at room temperature for 1 hour. Then all wells were washed three times with 0.1% PBST and blocked for 2 hours at room temperature using 1% BSA diluted with PBS, then the solution was discarded and washed three times with 0.1% PBST.
- the first, second and third input phages which are bipodal peptide binder recombinant phages, were divided into 800 ⁇ and 10% BSA 200 (iH in combination with 100 ⁇ each of 3 wells in ED-B, straptavidin and BSA wells). It was allowed to stand for 1 hour 30 minutes at 27 ° C. After washing 10 times with 0.1% PBST solution, HRP-conjugate anti-M13 antibody (GE Healthcare) was reacted with 1: 1,000 and reacted at 27 ° C. for 1 hour. After washing 5 times with 0.1% PBST, 100 ...
- Phages recovered at the biopanning stage with the highest output phage / input phage ratio were infected with XL1-BLUE cells and plated at about 100-200 plaques per plate. Using a sterile tip, 60 plaques were inoculated in 2 LB-ampicillins (50 cultures and shaken at 37 ° C for 5 hours.
- 0D from 0.8 to 1 by the addition of Ex helper phages of 5xi0 9 pfu heunhap at a rate of 200 rpm for one hour at 37 ° C, and were cultured.
- Culture medium to l then centrifuged for 10 min 000Xg supernatant ampicillin the removed and the precipitated cells (50 ⁇ / ⁇ ) and kanamycin (and resuspended in LB broth for 1 a 25 comprises from 30 ° C 200
- the cultures were incubated for one day at a rate of rpm, and the culture was centrifuged at 10,000Xg, 20 minutes, and 4 ° C.
- Busy ssikeul amplified for each phage peptide clone solution 100 ⁇ to all wells and wash was allowed to stand for 1.5 hours at 27 ° C. With 0.1% PBST 5 times, and then the solution HRP- conjugated anti -M13 antibody ( GE Healthcare) was diluted to 1: 1,000 and reacted for 1 hour at 27 ° C. After washing 5 times with 0.1% PBST, 100MB of TMB solution was used to induce color reaction, and then 100 M of 1 M HC1 was added. Clones were stopped and absorbances were measured at 450 nm to select clones with higher absorbance compared to BSA, and their phages were infected with XL1 cells and plated to about 100-200 plaques per plate.
- the matching primer is the vector sequence 5'-
- MyD88 is a bipodal peptide because it is a protein present in the cell. Korea) EDC / NHS (Sigma) was used to covalently bind the bipodal peptide binder to enable cell permeation. Since the amount of MMP-13 is increased when the activity of MyD88 is activated, it is possible to determine whether the activity of MyD88 is inhibited by measuring the amount of MMP-13. Cartilage cells were treated with IL-lbeta (10 ng / ml) (R & D systems, Minneapolis), which activates the activity of MyD88.
- chondrocytes were treated with MyD88-specific bipodal peptide binder (peptide 1 in Table 3f), mRNA was isolated after 12 hours, and RT-PCR was performed for MMP—13 and GAPDH.
- cartilage cells were destroyed to obtain intracellular proteins, followed by Western blotting using an Anti-MMP 13 antibody (Abeam, ab3208, Cambridge) and a semi-dry transfer machine (Amersham Bioscience, Piscat away) 3 ⁇ 4 ⁇ MMP-13. The amount of was measured.
- the structure stabilization site of the bipodal peptide binder As the structure stabilization site of the bipodal peptide binder, a stable beta-hairpin motif was used.
- tryptophan zippers (Andrea et al., Proc. Natl. Acad. Sci. 98: 5578-5583 (2001)) which stabilized the beta-hairpin motif structure by the interaction of tryptophan-tryptophan amino acids were used.
- Variable regions were created in two portions by randomly arranging six amino acids in each of the N- and C-terminal portions of the backbone tryptophan zipper (FIG. La).
- This is called a bipodal peptide binder and has variable regions on both sides so that it can be cooperatively attached to the antigen and thus have high affinity and specificity.
- the structure stabilization site of the bipodal peptide binder may be configured in various ways as shown in FIGS.
- the bipodal peptide binder library was subjected to biopanning three to five times for fibronectin ED-B, VEGF, VCAM1, nAchR, and HSA proteins, and the ratio of output phage / input phage of phage peptides recovered in each panning step was determined. (Table la). [Table la]
- Each input phage in the library of bipodal peptide binders was subjected to ELISA for ED-B, strapavidin and BSA.
- the reaction of the first input phage is similar in absorbance for ED—B, straptavidin and BSA, but the second input From phage, ED-B absorbance was 5.1 times higher than that of straptavidin and 3.4 times higher than that of BSA.
- ED-B absorbance was 22 times higher than that of straptavidin and 15 times higher than that of BSA, indicating that biopanning was successfully achieved for ED-B (FIG. 3 and Table 2). .
- Example 12 Phage Peptide Screening (Phase ELISA) and Sequencing Specific for Fibronectin ED-B, VEGF, VCAM1, nAchR, HSA and MyD88
- Phages recovered at the highest output / input ratio during the panning stage of each library were obtained in the form of plaques.
- ELISA was performed on BSA after amplifying 60 phages from each plaque (FIG. 4). Clones with higher absorbance than BSA were selected and requested for DNA sequencing. From this a peptide sequence specific to each overlapped protein was obtained (Table 3).
- Peptide 2 SANSLYGSWTWENG WTWKGTSRQRW
- Example 13 Determination of affinity of fibronectin ED-B, VEGF, VCAM1, nAchR and HSA
- peptides for fibronectin ED—B, VEGF, VCAM1, nAchR and HSA were synthesized and measured for affinity using the SPR Biacore system (Biacore AB, Uppsala, Sweden).
- affinity for fibronectin ED-B peptide 1 was 620. nM, peptide 2 showed 75 nM and peptide 3 showed 2.5 ⁇ (FIG. 5A).
- affinity of the fragment peptide of VCAM1 was measured and peptide 1 showed 318 nM (FIG. 5C).
- Peptide 1 showed 73 nM of the affinity of the fragment peptide of nAchR (Fig. 5d), peptide 1 showed 115 nM of the affinity of the fragment peptide of HSA (Fig. 5e).
- the solution was discarded and washed three times with 0.1% PBST.
- the recombinant phage having the peptide of the present invention was well mixed with 2% BSA, dispensed into wells containing 10 proteins by 100, and left at 27 ° C. for 2 hours.
- HRP—conjugated anti-M13 antibody (GE Healthcare) was diluted 1: 1,000 and reacted at 27 ° C. for 1 hour.
- HCSSAV N-terminal sequence
- IIRLEQ C-terminal sequence of Peptide2 that specifically bind ED-B to other ⁇ -hairpin skeletons GBlm3 and HP7 in addition to tryptophan zippers (Anigen, Korea). That is, the sequence of the bipodal peptide binder containing tryptophan zipper is HCSSAVGSWTWENGKWTWKGIIRLEQ, the bipodal peptide binder containing GBlm3 is HCSSAVGKKWTYNPAIXiKFTVQEGI IRLEQ, and the bipodal peptide binder including HP7 is HCSSAVGKTWNPATGKWTEG IIRLEQ.
- HSSAV ⁇ -terminal sequences
- IIRLEQ C-terminal sequences
- MyD 88 (5 g /) was placed in 10 wells of a 96 well ELISA plate (Corning), and then left overnight at 4 ° C., and blocked for 2 hours at room temperature using 2% BSA the next day. The solution was discarded and washed three times with 0.1% PBST. The bipodal peptide binder recombinant phage containing solution 800 ⁇ and 10% BSA 200 ⁇ were mixed and transferred to 10 wells to which Myd88 was bound and left at room temperature for 1 hour.
- Ampicillin 50 and 20 ⁇ glucose was mixed, then 2X1010 pfu of Ex helper phage was added and incubated at 37 ° C for 1 hour at 200 rpm. The culture was centrifuged at l, 000Xg for 10 minutes. The supernatant was then removed and resuspended in precipitated cells with Ampicillin (50 and 40 mi LB liquid medium containing kanamycin (25 g / m «), incubated at 30 ° C for 200 rpm and incubated for one day. The cultures were centrifuged at 4,000 ⁇ g, 20 min and 4 ° C.
- Phage peptide detection specific to MyD88 protein Phage ELISA
- HRP-conjugated anti—M13 antibody (GE Healthcare) was diluted 1: 1,000 and reacted at 27 0 C for 1 hour. After washing 5 times with 0.1% PBST, 100 ⁇ l of TMB solution was dispensed to induce color reaction, and then reaction was stopped by adding lOOul of 1M HC1. By measuring absorbance at 450 nm, clones with more than 20-fold higher absorbance of AR-DBD were selected. These phages were infected with XL1 cells and plated to 100-200 plaques per plate.
- Plaque was inoculated into 4 ml of LB-Ampici 11 in (50ug / ml) culture using a sterilized tip, followed by shaking culture at 37 ° C for 1 day.
- the plasmids were purified using a plasmid preparation kit for sequencing.
- the sequencing primer used the vector sequence 5-GAT TAC GCC AAG CTT TGG AGC -3 '.
- the bipodal-peptide binder library was biopanned 5 times for myd88 protein and the output phage / input phage ratio of the phage peptides recovered at each panning step was determined (Table 4a).
- ELISA was performed on BSA after amplifying 60 phages from each plaque. Clones with higher absorbance than BSA were selected and requested for DNA sequencing. From this, a peptide sequence specific to each overlapped protein was obtained.
- DBD Androgen receptor DNA binding domain
- Total mRNA was extracted from LNCaP cells, a prostate cancer cell line, and cDNA was generated using oligo dT.
- Two primers 5'- GAC TAT TAC ⁇ CCA CCC CA-3 '(AR_F1) and 5'-TAG TTT CAG ATT ACC AAG TTT C— 3 '(AR ⁇ Bl) was synthesized to produce 20 pmol of AR-F1, 20 pmol of AR-Bl, 2.5mM dNTP mixture 4y 1, Ex Taq DNA polymerase 1 ⁇ 1 (10 U), 10 x PCR buffer 5 ⁇ 1 was mixed and distilled water was added so that the total amount was 50 ⁇ l.
- This mixture was prepared by AR reaction to PCR reaction (94 5 minutes, 30 cycles: 57 ° C 30 seconds and 72 0 C 1 minutes, 94 0 C 30 seconds) and purified using a PCR purification kit.
- Two primers, 5'- TAT GGA TCC GAC TAT TAC TTT CCA CC— 3 '(AR_F1- BamHl) and 5'-ATA CTC GAG TCA TAG TTT CAG ATT ACC AAG-3' (AR_Bl-Xhol) was synthesized and mixed with 20 pmol of AR-F1, 20 pmol of AR-Bl, 4 ⁇ 1 of 2.5mM dNTP mixture, 1 ⁇ 1 of Ex Taq DNA polymerase (10 U), 5 ⁇ 1 of 10 x PCR buffer, and a total of 50 ⁇ 1.
- the mixed solution to which distilled water was added was made. This mixture was prepared by AR reaction to PCR reaction (94 0 C 5 min, 30 cycle: 57 ° C 30 sec and 72 0 C 1 min, 94 0 C 30 sec) and purified using PCR purification kit. .
- AR reaction to PCR reaction 94 0 C 5 min, 30 cycle: 57 ° C 30 sec and 72 0 C 1 min, 94 0 C 30 sec
- restriction enzyme treatment was performed on the AR-DBD insert gene and the pGEX-4T-1 vector. About 2yg of insert DNA was reacted with B HI (NEB) and i / (NEB) for 4 hours and purified using a PCR purification kit.
- Colonies grown on agar plate medium were inoculated into 5 ml of LB medium, incubated for 1 day while mixing at 200 rpm at 37 0 C, and then purified by plasmid preparation using a plasmid preparation kit. It was.
- the pGEX_4T_l vector cloned from Androgen receptor DBD was transformed into BL21 cells and plated in ampici 11 in agar medium.
- ImM isopropyl-pD-thiogalactopyranosidedPTG was added thereto, and the mixture was grown at 37 ° C. at 200 rpm for 8 hours. Centrifugation was performed at 4,000 g for 20 minutes to remove all supernatants except the sunk cells and resuspended in PBS buffer. Store at -80 ° C for one day, dissolve E. coli using Sonicator, and centrifuge for 1 hour at 15 ⁇ 000 g to attach supernatant to GST affinity resin. After washing the resin with PBS, N-terminal GST-AR DBD protein was collected using Elution buffer (25 mM glutathione, 50 mM Tris pH 8.8, 200 mM NaCl). The protein thus collected is subjected to gel filtration using superdex75 column and PBS (pH7.4) buffer to collect high purity GST-AR DBD protein.
- Elution buffer 25 mM glutathione, 50 mM Tris pH 8.8, 200 mM NaCl
- pGEX-4T-l vector itself was transformed into BL21 cells and plated in ampicillin agar medium. Colonies grown on agar plate medium were inoculated in 5ml LB medium loaded with ampicillin (25ug / ml) at a rate of 200 rpm at 37 ° C. After culturing for one day with mixing, it was transferred to 50ml ampicillin (25ug / ml) LB medium and grown for 3 hours. E. coli grown in this way was put in 2L LB ampicillin (25ug / ml), 50ml E. coli was added to 0DO.6-0.8.
- IPTG ImM isopropyl- ⁇ -D-thiogalactopyranoside
- EMSA was performed to determine whether the purified AR-DBD binds to DNA.
- 5'-CCA GAA CAT C GAA CAC-3 '5'-GTG TTC TTG ATG TTC TGG-3' a DNA sequence to which AR DBD binds, was synthesized. Then, a shift buffer (4 mMTris-HCl (pH7.5) , 80 mM NaCl, 0.5 mM ZnC12, 2.5 mM MgS04, 1 mM EDTA, 0.5 mM DTT, 1 lg polyCdl-dC) and 4% glycerol) were added and incubated with purified AR DBD and DNA. And retardation was confirmed by electrophoresis on agarose gel.
- GST-AR DBD 10ug / ml
- GST (10ug / ml) lml was placed in 96 well EL ISA plate (Corning). 50ul was added to 20wells and left overnight at 4 ° C. The next day, all 40 wells were washed three times with 0.1% PBST and blocked for 2 hours at room temperature using 2% BSA diluted with PBS. Then, the solutions were discarded and washed three times with 0.1% PBST.
- Bipodal-peptide binder recombinant phages containing solution and 800ul 10% BSA were combined well common to 200ul was placed in 20wells BSA coating on GST to ssegeo the phage attached to the streptavidin and BSA for 1 hour, placed in a 27 0 C. The supernatant was recovered and transferred to 20 wells with GST-AR-DBD attached at 27 0 C for 45 minutes. It was political. Remove all 20 wells of solution, wash 15 times with 0.5% PBST, add 1 ml of 0.2 M glycine / HCl (pH2.2) to 50ul / each well to elute the phage for 20 minutes and collect lml on E-tube.
- the PEG solution was completely removed, the phage peptide pellet was dissolved in 1 ml of PBS solution, and then used for secondary biopanning. The same method was used for each panning step, and the washing process was increased in steps of 0.5% PBST 25 and 35 times.
- Each input phage of the bipodal-peptide binder library was subjected to ELISA for GST, BSA, and GST-AR-DBD.
- All wells were washed three times with 0.1% PBST and blocked for 2 hours at room temperature using 2% BSA diluted with PBS. Then, the solutions were discarded and washed three times with 0.1% PBST.
- HRP-conjugated anti—M13 antibody (GE Healthcare) was diluted 1: 1,000 and reacted for 1 hour at 27 ° C. After washing 5 times with 0.1% PBST, 100 ⁇ of TMB solution was dispensed to induce color reaction, and then reaction was stopped by adding lOOul of 1M HC1. By measuring absorbance at 450 nm, clones with more than 20-fold higher absorbance of AR-DBD were selected. These phages were infected with XL1 cells and plated to 100-200 plaques per plate.
- Plaque was inoculated into 4 ml of LB-Ampici 11 in (50ug / ml) culture using a sterile tip, followed by shaking culture at 37 ° C for 1 day. Purification was commissioned. Sequencing primer was used as the vector sequence 5 ⁇ GAT TAC GCC AAG CTT TGG AGC -3 '.
- EMSA was performed to determine whether the synthesized bipodal-peptide binder inhibits the binding of AR-DBD to DNA.
- FITC was conjugated to the N-term of AR DBD BPB, and oligo 9R peptide, a cell permeation peptide, was conjugated to the lysine residue of the loop portion of BPB, and FITC-BPB-9R and FITC-BPB were 0.5yg for PC3 cell. Treated for 1 hour. After washing three times, the cells were fixed, and confocal microscopy confirmed that BPB had entered the cells.
- the bipodal-peptide binder library was biopanned 5 times for AR-DBD protein and the output phage / input phage ratio of the phage peptides recovered at each panning step was determined (Table 4b).
- ELISA was performed on AR-DBD, GST, and BSA for each input phage in the bipodal-peptide binder library.
- the absorbance of AR-DBD, GST, and BSA was similar, but from the third input phage, ED-B absorbance was 5.1 times higher than GST and 3.4 times higher than BSA.
- ED-B absorbance was higher than GST and BSA, indicating that biopanning was successfully performed on AR-DBD (FIG. 12A).
- Peptide 2 GGHNIQGSWTWENGKWTWKGWQHIWG (6/20 clones)
- EMSA was performed to determine whether the bipodal peptide binder binds to AR-DBD. As the BPB treatment concentration increased, AR-DBD gradually lost its ability to bind to DNA. This means that AR can block its ability to bind with DNA (FIG. 12C).
- the supernatants were taken at 8 ⁇ 5 ⁇ PEG / NaCl [20% PEG (w / v) and 15 % NaCl (w / v)] was added and then left for 1 hour at 4 ° C. After centrifugation, the PEG solution was completely removed and the phage peptide pellet was dissolved in 1 PBS solution and used for secondary biopanning. The same method was used for each panning step, and the washing process was increased 20 times and 30 times (0.1% PBST), respectively.
- BPB1 affinity was measured. Affinity was measured using Biacore X. STAT3 protein was fixed to 4000RU in pH5.5 buffer on the CM5 chip. And affinity was measured by peptide concentration 3 ⁇ 4 ⁇ , 5 ⁇ , 7.5 ⁇ . 4. Cell Delivery Experiment of Bipodal Peptide Binder Specific for STAT3
- FITC was conjugated to N-term of STAT3 BPB1 peptide (QAYYIP GSWTWENGKWTWKG LWGPEF), and oligo 9R peptide, a cell permeation peptide, was conjugated to the lysine residue of the loop portion of BPB.
- FITC-BPB-9R and FITC-BPB were treated in PC3 cells for 1 hour. After washing three times, the cells were fixed, and confocal microscopy confirmed that BPB had entered the cells.
- Oligo 9R a cell-penetrating peptide
- STAT3 BPB1 peptide QYYIP GSWTWENGKWTWKG LWGPEF
- FITC was conjugated to the N-terminal.
- FITC-BPB-9R and FITC-BPB were treated in PC3 cells for 1 hour. After washing three times, the cells were fixed, and confocal microscopy confirmed that BPB had entered the cells.
- the bipodal-peptide binder library was subjected to biopanning for Stat3 protein for 4 times and the output phage / input phage ratio of phage peptides recovered at each panning step was determined (Table 4c).
- the phage recovered in the 4th stage with the highest 0/1 ratio among the panning stages of each library was secured in the form of plaque.
- ELISA was performed on STAT3 and streptaividin (FIG. 13A).
- DNA sequencing of six clones with more than twice the absorbance of streptavidin showed two sequences: Peptidel: QAYYIP GSWTWENGKWTWKG LWGPEF; Peptides HGFQWP GSWTWENGKWTWKG AYQFLK
- FIG. 13B is an experimental result for Peptide 1 (QAYYIP GSWTWENGKWTWKG LWGPEF)
- FIG. 13C is an experimental result for Peptide2 (HGFQWP GSWTWENGKWTWKG AYQFLK).
- SPRCBiacore X was used to measure the affinity of the bipodal peptide binder.
- BBPl QAYYIP GSWTWENGKWTWKG LWGPEF
- the cell penetrating peptide and FITC were added to the loop of the bipodal peptide binder and introduced into the cell through confocal microscopy. With and without OHgo-9 R peptide, a cell penetrating peptide As a result of the comparison, it was confirmed that the cell penetrating peptides effectively enter the cells (FIG. 13E).
- STAT3-specific BPB Peptide 1; QAYYIP GSWTWENG WTWKG LWGPEF
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/515,026 US20120309934A1 (en) | 2009-12-11 | 2010-12-03 | Intracelluar targeting bipodal peptide binder |
JP2012543021A JP5677454B2 (ja) | 2009-12-11 | 2010-12-03 | 細胞内ターゲット結合用二座ペプチドバインダー |
KR1020127015777A KR20120125455A (ko) | 2009-12-11 | 2010-12-03 | 세포내 타겟 결합용 바이포달 펩타이드 바인더 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0123134 | 2009-12-11 | ||
KR20090123134 | 2009-12-11 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011071280A2 true WO2011071280A2 (ko) | 2011-06-16 |
WO2011071280A9 WO2011071280A9 (ko) | 2011-08-25 |
WO2011071280A3 WO2011071280A3 (ko) | 2011-11-10 |
Family
ID=44146029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/008646 WO2011071280A2 (ko) | 2009-12-11 | 2010-12-03 | 세포내 타겟 결합용 바이포달 펩타이드 바인더 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20120309934A1 (ko) |
JP (1) | JP5677454B2 (ko) |
KR (1) | KR20120125455A (ko) |
WO (1) | WO2011071280A2 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013061818A1 (ja) * | 2011-10-25 | 2013-05-02 | 国立大学法人岡山大学 | 新規ペプチド複合体、そのハイブリッド複合体およびその用途 |
US20140296479A1 (en) * | 2011-04-08 | 2014-10-02 | Gwangju Institute Of Science And Technology | D-aptide and retro-inverso aptide with maintained target affinity and improved stability |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107011415A (zh) | 2008-10-20 | 2017-08-04 | 光州科学技术院 | 双齿肽结合物 |
KR102092345B1 (ko) | 2013-09-30 | 2020-03-24 | 삼성전자주식회사 | 류신 지퍼 변이체 및 이의 용도 |
KR101531944B1 (ko) * | 2013-12-24 | 2015-06-29 | 광주과학기술원 | Vegf에 특이적으로 결합하는 vegf-bpb |
KR20150118252A (ko) * | 2014-04-11 | 2015-10-22 | 한국과학기술원 | 환형의 β-헤어핀 기반 펩타이드 바인더 및 이의 제조방법 |
KR102272213B1 (ko) | 2014-07-08 | 2021-07-01 | 삼성전자주식회사 | 표적화 부위, 절단 부위, 및 세포막 투과 부위를 포함하는 융합 단백질 및 그의 용도 |
JP2019535704A (ja) | 2016-11-11 | 2019-12-12 | ユニバーシティ オブ コペンハーゲン | 結合性ペプチド |
KR101971092B1 (ko) * | 2017-06-28 | 2019-04-23 | 한국세라믹기술원 | 아세틸콜린수용체 결합 펩타이드 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180343B1 (en) * | 1998-10-08 | 2001-01-30 | Rigel Pharmaceuticals, Inc. | Green fluorescent protein fusions with random peptides |
US20030166003A1 (en) * | 1999-06-14 | 2003-09-04 | Cochran Andrea G. | Structured peptide scaffold for displaying turn libraries on phage |
JP2003502304A (ja) * | 1999-06-14 | 2003-01-21 | ジェネンテック・インコーポレーテッド | ターンライブラリをファージ上に表示するための構造化ペプチド骨格 |
US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
US6914123B2 (en) * | 2001-04-17 | 2005-07-05 | Genentech, Inc. | Hairpin peptides with a novel structural motif and methods relating thereto |
ES2491166T3 (es) * | 2003-11-15 | 2014-09-05 | Polyphor Ltd. | Miméticos de lazo de horquilla beta fijados a patrón y su utilización en exposición en fagos |
EP1812472A1 (en) * | 2004-11-04 | 2007-08-01 | Genentech, Inc. | Polypeptides that bind baff and/or april |
WO2008008923A2 (en) * | 2006-07-12 | 2008-01-17 | Oncotx, Inc. | Compositions and methods for targeting cancer-specific transcription complexes |
JP2008200011A (ja) * | 2007-02-22 | 2008-09-04 | Toray Ind Inc | 細胞内移行性ペプチド、それを含有する医薬組成物及びその使用方法 |
AU2008271050B2 (en) * | 2007-06-29 | 2014-11-06 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
-
2010
- 2010-12-03 US US13/515,026 patent/US20120309934A1/en not_active Abandoned
- 2010-12-03 JP JP2012543021A patent/JP5677454B2/ja not_active Expired - Fee Related
- 2010-12-03 WO PCT/KR2010/008646 patent/WO2011071280A2/ko active Application Filing
- 2010-12-03 KR KR1020127015777A patent/KR20120125455A/ko not_active Application Discontinuation
Non-Patent Citations (4)
Title |
---|
DEECHONGKIT, S. ET AL.: 'Beta-sheet folding mechanisms from perturbation energetics.' CURRENT OPINION IN STRUCTURAL BIOLOGY. vol. 16, no. 1., February 2006, pages 94 - 101 * |
GANGULY, S. ET AL.: 'Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted against HIV-1 transactivation response element.' OLIGONUCLEOTIDES. vol. 18, no. 3, September 2008, pages 277 - 86 * |
ROBINSON, J. A. ET AL.: 'Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I.' BIOORGANIC & MEDICINAL CHEMISTRY. vol. 13, no. 6, 15 March 2005, pages 2055 - 64 * |
ROBINSON, J. A.: 'Beta-hairpin peptidomimetics: design, structures and biological activities.' ACCOUNTS OF CHEMICAL RESEARCH. vol. 41, no. 10, October 2008, pages 1278 - 88 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140296479A1 (en) * | 2011-04-08 | 2014-10-02 | Gwangju Institute Of Science And Technology | D-aptide and retro-inverso aptide with maintained target affinity and improved stability |
WO2013061818A1 (ja) * | 2011-10-25 | 2013-05-02 | 国立大学法人岡山大学 | 新規ペプチド複合体、そのハイブリッド複合体およびその用途 |
JPWO2013061818A1 (ja) * | 2011-10-25 | 2015-04-02 | 国立大学法人 岡山大学 | 新規ペプチド複合体、そのハイブリッド複合体およびその用途 |
Also Published As
Publication number | Publication date |
---|---|
JP2013513382A (ja) | 2013-04-22 |
KR20120125455A (ko) | 2012-11-15 |
WO2011071280A9 (ko) | 2011-08-25 |
JP5677454B2 (ja) | 2015-02-25 |
US20120309934A1 (en) | 2012-12-06 |
WO2011071280A3 (ko) | 2011-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101151805B1 (ko) | 바이포달 펩타이드 바인더 | |
WO2011071280A2 (ko) | 세포내 타겟 결합용 바이포달 펩타이드 바인더 | |
Udugamasooriya et al. | A peptoid “antibody surrogate” that antagonizes VEGF receptor 2 activity | |
JP5677453B2 (ja) | Bpbベースのカーゴ運搬システム | |
US20210061856A1 (en) | Cell-permeable stapled peptide modules for cellular delivery | |
KR20200038303A (ko) | 모듈형 결합 단백질 | |
US20140296479A1 (en) | D-aptide and retro-inverso aptide with maintained target affinity and improved stability | |
WO2015156644A1 (ko) | 환형의 β-헤어핀 기반 펩타이드 바인더 및 이의 제조방법 | |
WO2011132940A2 (ko) | Rtk에 특이적으로 결합하는 rtk-bpb | |
WO2011132938A2 (ko) | Gpcr에 특이적으로 결합하는 gpcr-bpb | |
Iwamoto et al. | Mirror-Image Human Serum Albumin Domain III as a Tool for Analyzing Site II-Dependent Molecular Recognition | |
Darlot | Design of modulatory peptides against chemokines | |
KR101443839B1 (ko) | 펩타이드의 타겟 친화도 개선방법 | |
CN118005762A (zh) | 靶向清道夫受体的多肽配体、非共价双靶向分子及其制药用途 | |
KR20130103301A (ko) | 전사인자에 특이적으로 결합하는 tf-bpb | |
KR20110116930A (ko) | 이온채널에 특이적으로 결합하는 이온채널―bpb | |
WO2011132939A2 (ko) | Rtk에 특이적으로 결합하는 rtk-bpb | |
Levine | Functional Biomimetic Architectures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10836176 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012543021 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20127015777 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13515026 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10836176 Country of ref document: EP Kind code of ref document: A2 |